MediciNova (NASDAQ:MNOV) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV) in a report released on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.

MediciNova Price Performance

Shares of MediciNova stock opened at $1.90 on Friday. The stock has a market cap of $93.19 million, a P/E ratio of -11.18 and a beta of 0.72. The stock’s 50 day simple moving average is $1.43 and its 200-day simple moving average is $1.41. MediciNova has a 1-year low of $1.12 and a 1-year high of $2.38.

MediciNova (NASDAQ:MNOV) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. As a group, research analysts expect that MediciNova will post -0.23 EPS for the current fiscal year.

About MediciNova

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.